Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MV-ZIKA-RSP
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Vector Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MV-ZIKA-RSP is a live attenuated recombinant viral vectored vaccine developed for the prophylaxis of Zika virus infection in healthy adults. It utilizes a measles virus vector platform to express Zika virus antigens and is designed to induce protective immune responses against ZIKV. The vaccine was selected after preclinical studies demonstrated immunogenicity and efficacy in animal models, including mice and non-human primates. Clinical development included GMP manufacturing, toxicity studies, and a phase I clinical trial in Austria that showed the vaccine was well tolerated and induced immune responses. The developer is Themis Bioscience (a subsidiary of Merck & Co), using their proprietary Themaxyn vector technology[2][4][5].
- Other names
- measles virus-based Zika vaccinerecombinant measles virus expressing Zika E protein
02
Targets
SLAMF1 (SLAM family member 1)
Beyond the preview
Go deeper on MV-ZIKA-RSP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MV-ZIKA-RSP.